August 17, 2021 – Los Angeles, CA – Pioneering liquid medical company ALT (Advanced Liquid Technology), announces it has entered into an agreement with Grow (Grow Group Plc) to market and distribute their proprietary, fast-acting, liquid products across Europe.
ALT uses emulsion technology to create unique flavor neutral, zero-calorie, sugar-free, vegan, keto, and paleo-friendly water-compatible medical products in the form of nanoemulsions, which are kinetically stable with incredibly small particle size. ALT’s technology allows for far more effective delivery of cannabinoids to the user, compared to tinctures and other ingestible products.
Patients will benefit from the rapid onset of effects within 5-15 minutes in addition to higher efficiency in absorption. ALT finally enables doctors to recommend precise doses of cannabinoids to patients based on their individual need for relief from an array of ailments. ALT’s products are designed to allow patients to titrate their dose accordingly.
ALT plans to have a range of EU GMP-certified liquid medical products available for patients in the UK and Germany by early 2022. Medical patients will have access to ALT’s products by obtaining prescriptions through private practice or national health services.
Grow Group’s CEO Ben Langley said that “GROW’s mission is to bring medical products to all patients who need it. We strive to constantly improve and innovate on our product offering. With our leading position and unique experience we are very confident that with ALT’S new mode of administration using liquid we are going to make another leap forward in providing patients with the best products and solutions for their symptom management.”
ALT’s CEO, Robert Davis, commented, “We are honored to partner with Grow in bringing ALT’s completely differentiated brand and liquid medical technologies to the European medical markets. After successfully launching ALT into California in December of 2020, we are excited to expand internationally, our first step in becoming a global brand. ALT’s mission is to Enhance Human Potential and we will do so, one patient at a time, through the power of our liquid medicine platform.”
Bar Capital Global introduced and advised both ALT and Grow on this groundbreaking relationship and will continue to assist in the successful launch of the products.
Media ContactCompany Name: Grow PharmaContact Person: Pierre VanWeperenEmail: Send EmailPhone: +447885575807Country: United KingdomWebsite: https://growgroupplc.com/pharma/
